IFNG and non-small cell lung carcinoma: Immunotherapy has revolutionized the treatment of advanced NSCLC, demonstrating effective activity in metastatic cases and improving the 5‐year survival rate.[44, 45] Our previous meta‐analysis found that NSCLC patients with BM who received immunotherapy had better outcomes than those who did not.[46] Previous studies have also indicated a correlation between T cell signature/IFNγ and the response to cancer immunotherapy.[25, 26, 27, 47, 48] Therefore, we explored the relationship between radiomic features and gene sets associated with predicting response to immunotherapy.